Why This Small Biotech Stock Just Rocketed 176%

Prometheus Biosciences (RXDX) reported promising results for one of its drugs in two inflammatory disease studies on Wednesday, and RXDX stock catapulted by triple digits.X The company studied its drug, currently dubbed PRA023, in patients with ulcerative colitis and Crohn's disease, two forms of…#buckingrecentnegativepressure #pra023 #pfe #crohn #rxdxstocktargetingaligandprometheu #gregoryrenza #svbsecurities #rbccapitalmarkets #pfizerroivant #rbc
Source: Reuters: Health - Category: Consumer Health News Source Type: news